Amendment To Cervical Cancer Bill Would Require HPV Labeling For Condoms
This article was originally published in The Gray Sheet
Executive Summary
Condoms manufactured 180 days after the enactment of breast and cervical cancer treatment legislation pending in the House would require a statement in labeling that condoms do not provide adequate protection against the transmission of human papillomavirus (HPV), according to an amendment unanimously adopted by the House Commerce Committee during its Oct. 29 mark-up of the legislation.